Urogenital infections in patients with diabetes mellitus: Beyond the conventional aspects.
MAGI
UTIs
balanitis
diabetes mellitus
urogenital infections
vaginitis
Journal
International journal of immunopathology and pharmacology
ISSN: 2058-7384
Titre abrégé: Int J Immunopathol Pharmacol
Pays: England
ID NLM: 8911335
Informations de publication
Date de publication:
Historique:
entrez:
8
2
2020
pubmed:
8
2
2020
medline:
23
5
2020
Statut:
ppublish
Résumé
Diabetes mellitus (DM) is a widespread disease in our country. Urogenital infections, including urinary tract infections, vaginitis, balanitis, balanoposthitis, and male accessory gland infections, show a higher risk of occurrence in patients with DM that non-diabetic subjects. Both non-drug-related and drug-related mechanisms are involved in their pathogenesis. These conditions may impact on glucose control and islets function in DM and more likely develop into adverse complications. A throughout microbial characterization, including the drug-sensitivity test, is required for a proper management. To reduce the risk of recurrence, combined treatment, including antibiotic, anti-inflammatory, and fibrinolytic molecules, should be prescribed also to the sexual partner. The choice of the antidiabetic drug to prescribe should take into consideration the presence of urogenital infections. In conclusion, urogenital infections may more likely lead to complication in diabetic than non-diabetic patients, affect fertility and glucose control. Therefore, they need proper management.
Identifiants
pubmed: 32031031
doi: 10.1177/2058738419866582
pmc: PMC6728654
doi:
Substances chimiques
Anti-Bacterial Agents
0
Hypoglycemic Agents
0
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
2058738419866582Références
Int J Androl. 2011 Oct;34(5 Pt 2):e330-47
pubmed: 21696400
Medicine (Baltimore). 2018 Oct;97(43):e12843
pubmed: 30412076
Asian J Androl. 2011 Nov;13(6):872-6
pubmed: 21804571
Front Endocrinol (Lausanne). 2018 May 25;9:268
pubmed: 29887834
Eur J Radiol. 2011 Nov;80(2):e64-7
pubmed: 20800402
Int J Dermatol. 2009 Feb;48(2):121-4
pubmed: 19200183
J Pak Med Assoc. 2017 Jan;67(1):143-145
pubmed: 28065975
J Endocrinol Invest. 2013 Oct;36(9):770-4
pubmed: 23633651
Am J Reprod Immunol. 2018 Dec;80(6):e13063
pubmed: 30294818
Andrology. 2017 Nov;5(6):1064-1072
pubmed: 28992374
Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):3112-3120
pubmed: 31002161
Ther Clin Risk Manag. 2018 Feb 26;14:403-408
pubmed: 29520146